Table 2.
Results From ELISA Validation (mg/L) of the Proteins From iTRAQ That Met ELISA Confirmation
| Up-reg | Down-reg | p-Value Binomial | Mean ± SD for Case | Mean ± SD for Control | p-Value Paired t-Test | Mean ± SD of Pair Differences | Median (Range) of Pair Differences | p-Value Signed Rank Test | |
|---|---|---|---|---|---|---|---|---|---|
| PREOP | |||||||||
| CRP | 48 | 27 | 0.01 | 7.2 ± 8.4 | 3.5 ± 5.6 | <.01 | 3.7 ± 10.7 | 1.6 (−1.6, 7.9) | <.01 |
| HPX | 40 | 35 | 0.32 | 1210.2 ± 285.3 | 1299.4 ± 524.3 | 0.06 | −89.2 ± 412.2 | 13.0 (−185.8, 113.0) | 0.46 |
| ORM1 | 44 | 31 | 0.08 | 859.4 ± 324.6 | 784.3 ± 299.1 | 0.13 | 75.2 ± 427.5 | 40.0 (−222.0, 303.0) | 0.22 |
| AZGP1 | 25 | 50 | 0.00 | 36.0 ± 8.5 | 40.3 ± 10.0 | 0.00 | −4.2 ± 12.6 | −2.8 (−11.0, 3.1) | 0.00 |
| POD2 | |||||||||
| CRP | 53 | 22 | <0.01 | 190.5 ± 62.5 | 140.8 ± 64.8 | <0.01 | 49.7 ± 93.2 | 63.8 (−22.3, 126.2) | <.01 |
| SERPINA3 | 41 | 34 | 0.24 | 528.2 ± 249.7 | 480.5 ± 198.5 | 0.05 | 47.8 ± 210.8 | 16.7 (−66.9, 172.6) | 0.07 |
| HPX | 41 | 34 | 0.24 | 1002.2 ± 277.9 | 1007.8 ± 251.0 | 0.82 | −5.6 ± 213.0 | 17.0 (−135.0, 136.1) | 0.87 |
| ORM1 | 37 | 38 | 0.59 | 1306.2 ± 347.9 | 1287.3 ± 325.3 | 0.69 | 18.9 ± 409.8 | −9.0 (−234.0, 254.0) | 0.69 |
| AZGP1 | 28 | 47 | 0.02 | 29.9 ± 7.3 | 32.7 ± 7.7 | 0.02 | −2.77 ± 9.9 | −3.6 (−9.0, 3.5) | 0.01 |
Note: SERPINA3 = alpha-1 antichymotrypsin (Genway Biotech); ORM1 = alpha-1 glycoprotein (R&D Systems); CRP = C-reactive protein (R&D Systems); down-reg = downregulated; HPX = hemopexin (Genway Biotech); POD2 = postoperative day 2; PREOP = preoperative; up-reg = upregulated; AZGP1 = zinc-alpha2-glycoprotein (AdipoGen Life Sciences). N = 150 (75 matched pairs). If two of the three statistical tests were significant (p < .10, bolded) at PREOP or POD2, then protein was considered validated by ELISA. Our correlation analyses indicated that CRP was moderately correlated with: SERPINA3 at PREOP and POD2 (r = 0.41 and 0.34, respectively, p < .0001 for both), and IL-6 (r = 0.46, p < .0001).